VIVUS is a pharmaceutical company dedicated to the development and commercialization of therapeutic products. The company's portfolio includes investigational products addressing obesity and sexual health.
Missing: VIVUS's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: VIVUS's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
VIVUS has filed 1 patent.
Diabetes, Obesity, Nutrition, Syndromes, Rare diseases
Diabetes, Obesity, Nutrition, Syndromes, Rare diseases
Latest VIVUS News
Nov 9, 2022
News Provided By Share This Article Anti-Obesity Prescription Drugs Market Growth, Trends and Forecast Anti-Obesity Prescription Drugs Market is expected to reach USD 1.2 billion by 2030, growing at a CAGR of 6.8% during the forecast period. NEW YORK CITY, NEW YORK, UNITED STATES, November 9, 2022 / EINPresswire.com / -- A variety of small and medium-sized businesses have entered the ' Anti-Obesity Prescription Drugs ' market, creating high competition, Market.us research has revealed in a new report. To ensure a solid footing, Local companies are being sought out by organizations to collaborate. The players are also interested in product diversification, product portfolio expansion, and deep research. Then Check Out Below! You have no time to read the complete article. Then you can check out these Ortho Anti-Obesity Prescription Drugs. Also, I have shared a buying guide [What Advantages should be in it] that will let you know the important things that you should Consider in Anti-Obesity Prescription Drugs Market. - Identifying and analyzing the top players and their strategies. - Understanding the competitive landscape. - Identifying consumer insights. - You can strategize for entering the market. Our highly skilled analysts from around the world have conducted extensive secondary and primary research to create this research study. The market study examines industry dynamics and the driving factors that are driving current market growth. This report also highlights the opportunities and limitations of this industry. To get a complete view of the factors that impact keyword market development across the globe, key industrial factors like macroeconomic and microeconomic factors have been studied in detail using PESTEL analysis. Complex algorithms are used to forecast market growth, such as sentiment analysis of end-users, regression analysis, and so on. Please connect with our representative, who will ensure you to get a report sample here @ https://market.us/report/anti-obesity-prescription-drugs-market/request-sample/ Note 1: Only Business E-mail id will be Prioritized This report contains first-hand information, quantitative and qualitative assessments from industry analysts, inputs by industry experts, and industry participants throughout the value chain. The report includes a detailed analysis of market trends and macroeconomic indicators, as well as market attractiveness according to segments. The report also provides qualitative information about the market impact of different market factors on specific market segments and geographies. Who Are Top Winning? New product launches, portfolio expansion, strategic collaborations, and mergers are some of the strategies used by the aforementioned companies to stay afloat in the Anti-Obesity Prescription Drugs market. Some of the key players operating in the Anti-Obesity Prescription Drugs market [In no particular order of Rank] are F Hoffmann La Roche Ltd, Orexigen Therapeutics Inc, Novo Nordisk A/s, Arena Pharmaceuticals Inc, Glaxosmithkline, Vivus Inc, Boehringer Ingelheim, Alizyme. Note 2: If any Company(ies) of your interest has/have not been disclosed in the above list then please let us know the same so that we will check the data available in our database and provide you the confirmation or inclusion in the final deliverables. This report addresses: - Estimates and forecasts from 2015 to 2032 - Market Growth opportunities and trend analyses - Market Segment and regional revenue forecasts for assessment 2022-2032 - Competition strategy and market share analysis - Product innovation listing for you to stay ahead of the curve - COVID-19's impact and how to sustain in these fast-evolving markets For any Queries Linked with the Report, Ask an Analyst@ https://market.us/report/anti-obesity-prescription-drugs-market/#inquiry Get Valuable Insights into Anti-Obesity Prescription Drugs Market: Anti-Obesity Prescription Drugs Market - Segmentation The global Anti-Obesity Prescription Drugs market is segmented on the basis of product type and by application type. The pricing analysis of the Anti-Obesity Prescription Drugs market can be done on the basis of product type segment. Application Segment Analysis: Some of the key applications as follow: Pediatric Anti-Obesity Prescription Drugs Market: Region Segment Analysis On the basis of geography, global Anti-Obesity Prescription Drugs market region is segmented into North America, Latin America, Asia-Pacific excluding Japan (APEJ), Eastern Europe, Western Europe, Middle East & Africa (MEA), and Japan. Among these regions, North America is presently leading the global Anti-Obesity Prescription Drugs market. Along with North America, Asia Pacific Anti-Obesity Prescription Drugs market is projected to grow at a significant rate during the forecast period due to major investments. The demand for Anti-Obesity Prescription Drugs is also anticipated to register high growth in global hubs such as Europe and Latin America region. Get Online Access to Research Libraries and Information Centers Industry Research@ https://market.us/report-library FAQs or How Report will help you and the inclusions Q.1. How big is the Anti-Obesity Prescription Drugs market? Q.2. What is the projected market size & growth rate of the Anti-Obesity Prescription Drugs Market? Q.3. What are the key driving factors for the growth of the Anti-Obesity Prescription Drugs Market? Q.4. What are the key trends in the Anti-Obesity Prescription Drugs market report? Q.5. What is the total market value of Anti-Obesity Prescription Drugs market report? Q.6. What segments are covered in the Anti-Obesity Prescription Drugs Market Report? Q.7. Who are the key players in Anti-Obesity Prescription Drugs market? Q.8. Which region has the highest growth in Anti-Obesity Prescription Drugs Market? Access Full Report Description with TOC @ https://market.us/report/anti-obesity-prescription-drugs-market/ Examined in the study are: - Anti-Obesity Prescription Drugs Market behavior, risk and opportunity levels - An assessment of end-industry behavior and opportunity - An anticipated timeline for Anti-Obesity Prescription Drugs industry recovery MORE RELATED REPORTS FROM OUR DATABASE: Report Statistics: DeNOx Catalyst : Opportunity And Challenges About Market.us Market.US provides customization to suit any specific or unique requirement and tailor-makes reports as per request. We go beyond boundaries to take analytics, analysis, study, and outlook to newer heights and broader horizons. We offer tactical and strategic support, which enables our esteemed clients to make well-informed business decisions and chart out future plans and attain success every single time. Besides analysis and scenarios, we provide insights into global, regional, and country-level information and data, to ensure nothing remains hidden in any target market. Our team of tried and tested individuals continues to break barriers in the field of market research as we forge forward with a new and ever-expanding focus on emerging markets. We have many reasons to recommend us: - Market.us cover more than 15 major industries, segmented into more than 90 sectors. - More than 120 countries - More than 100 paid data sources were mined for investigation. - Ask our research experts any questions you may have before or after you purchase your report. - Develop an overview of the current Water Meter landscape in key markets - Learn how regulatory or legal changes will affect the market - Identify market prospects
VIVUS Web Traffic
VIVUS Frequently Asked Questions (FAQ)
When was VIVUS founded?
VIVUS was founded in 1991.
Where is VIVUS's headquarters?
VIVUS's headquarters is located at 900 East Hamilton Avenue, Campbell.
What is VIVUS's latest funding round?
VIVUS's latest funding round is Loan.
How much did VIVUS raise?
VIVUS raised a total of $1.5M.
Who are the investors of VIVUS?
Investors of VIVUS include Paycheck Protection Program, Chilton Investment Company, Caxton Associates, Domain Associates, UBS and 20 more.
Who are VIVUS's competitors?
Competitors of VIVUS include Aerie, Clarus Therapeutics, Portola Pharmaceuticals, ARIAD Pharmaceuticals, BioMarck Pharmaceuticals and 12 more.
Compare VIVUS to Competitors
BioSante is a specialty pharmaceutical company focused on developing products for female sexual health, menopause, contraception and male hypogonadism. BioSante's key products are LibiGel® (testosterone gel) in Phase III clinical development under an SPA, to treat female sexual dysfunction, and Elestrin (estradiol gel), FDA approved to treat hot flashes in menopausal women. The current market for testosterone and estrogen products is approximately $2.5 billion dollars in the U.S. alone, with estimates for female sexual dysfunction potentially adding $2.0 - $4.0 billion, and the current market for hormonal contraception is approximately $3.0 billion.
Scientists at Epeius Biotechnologies have developed a targeted delivery system (TDS) that can transport genes or other therapeutic agents directly to diseased areas in the body. This pathotropic, or disease-seeking, technology has enabled the company to develop Rexin-G, a tumor-targeted, injectable gene delivery system that has demonstrated remarkable safety and single-agent efficacy in clinical trials internationally. Rexin-G is currently in clinical trials for pancreatic cancer in the U.S. ƒƒ‚ƒš‚" where it has achieved FDA orphan drug status ƒƒ‚ƒš‚" and has accelerated approval in the Philippines for the treatment of all solid tumors that are resistant to standard chemotherapy. The company's international clinical outreach with Rexin-G has enabled us to expedite further demonstrations that Rexin-G is highly active in a broad spectrum of chemo-resistant tumor types with efficacy and excellent safety profiles. The company are a biopharmaceutical company focused on expanding the therapeutic utility and commercialization of the company's pathotropic approach to disease treatment through internal development and commercialization of the company's oncology products and cancer vaccines, and through strategic partnerships in additional areas of oncology, immunology, cardiovascular, ocular, and wound healing applications, precision targeted diagnostics, and stem cell technologies.
BioMarck Pharmaceuticals is a biopharmaceutical company dedicated to the discovery and development of drugs for the treatment of pulmonary diseases and disorders associated with the over-secretion of mucus and pulmonary inflammation. In developing its lead compound, BIO-11006 Inhalation Solution, BioMarck has chosen chronic obstructive pulmonary disease (specifically chronic bronchitis) as its first target, but other diseases including asthma, and cystic fibrosis are later disease targets. BIO-11006 Inhalation Solution works by a novel dual mechanism; it inhibits both the secretion of mucus in the lungs and pulmonary inflammation. These aspects of BIO-11006 Inhalation Solution have been demonstrated in several different animal models. In addition, BioMarck has completed a full panel of preclinical safety studies, has an active IND with the FDA, has completed two BIO-11006 in Phase 1 clinical studies, and is currently conducting a Phase 2 study of the efficacy of BIO-11006 in COPD patients.
Oligomerix is a clinical-stage biotechnology company. It focuses on developing disease-modifying therapeutics for neurodegenerative diseases characterized by the aberrant tau protein, ranging from tauopathies such as progressive supranuclear palsy and frontotemporal dementia to Alzheimer’s disease. The firm serves clients in the healthcare sector. Oligomerix was founded in 2006 and is based in West Harrison, New York.
Argenes, Inc. is a Japanese bio-venture established in April 2004 focusing primarily on the development of biopharmaceuticals and molecular targeting therapeutics, including anti-rheumatoid arthritis (RA), and anti-osteoarthritis. Currently, the company's most innovatory prospective candidate for the treatment of RA is the drug anti-Fas mAb ARG098. The company operate preclinical and clinical studies as well as manufacturer pharmaceuticals through managing of CRO and CMO. At Argenes, Inc. the company continually seek to expand globally through creating alliances and through licensing out development rights and marketing rights.
Oraceuticals uses biotechnologies to develop drugs that advance oral treatment and improve oral health. Focuses on producing bioactive molecules that target chronic oral infections and control inflammation.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.